{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-21-000032","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.273519+00:00","generated_at":"2026-06-29T13:21:00.079121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Black Diamond Therapeutics reports Q2 2021 cash of $263.5M; pipeline advancing","bullets":["Cash, equivalents, and investments $263.5M as of June 30, 2021; expected to fund operations into 2023.","R&D expenses $26.7M vs $10.2M in Q2 2020; net cash used in operations $49.6M.","BDTX-189 Phase 1 data presented at ASCO; Phase 2 initiation on track for H2 2021 after FDA dialogue.","IND filings planned: BDTX-1535 in H1 2022, BRAP and FGFR programs in 2022.","Appointed Elizabeth Buck as CSO, Karsten Witt as interim CMO; Drs. Humphrey and Roberts departed; Mark Velleca added to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-21-000032","json":"https://secwatch.observer/filing/0001701541-21-000032.json","markdown":"https://secwatch.observer/filing/0001701541-21-000032.md","text":"https://secwatch.observer/filing/0001701541-21-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154121000032/0001701541-21-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154121000032/bdtx-20210812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:21:00.079121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}